• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

EHA: Survival data sets Daiichi Sankyo’s quizartinib back on track

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jun 13, 2022 at 11:02: AM
via Three years after Daiichi Sankyo’s FLR3 inhibitor quizartinib was rejected by the FDA, the drugmaker has reported the results of a new phase 3 trial that is key to getting the drug to the US market and chasing down rival drugs from Astellas and Novartis.

article source
 




Top Bottom
Back
Quote